ERBB2 and breast carcinoma: The current standard of care for HR‐positive, HER2‐negative advanced breast cancer (ABC) involves endocrine therapy, with or without cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors.4, 5, 6